XPO1 and thyroid gland undifferentiated (anaplastic) carcinoma: Inhibition of CRM1 has shown benefits in slowing down cancer growth and overcoming drug resistance to chemotherapeutic agents in several cancers including anaplastic thyroid cancer (ATC) [37,38,39,40,41,42].